When cancer comes back after treatment—or doesn’t respond at all—it can feel like the options are running out. But science is moving fast, and a new therapy called Terbium-161 FAPI is offering fresh hope to patients with relapsed or refractory solid…
🌟 Terbium-161 DOTATATE: A New Option for Neuroendocrine Tumors That Resist Standard Treatment
Living with a neuroendocrine tumor (NET) can be a long journey filled with ups and downs. For many patients, Lutetium-177 DOTATATE (Lu-177 PRRT) has been a game-changer—slowing tumor growth and improving quality of life. But what happens when the tumor stops…